Reply to thread

Message: [QUOTE="greenmedinfo, post: 4918"] PMID: Acta Pharm Sin B. 2021 Nov ;11(11):3542-3552. Epub 2021 Mar 22. PMID: 34900535 Abstract Title: Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemiamTOR/P70S6K/SREBPs pathway. Abstract: The mammalian target of rapamycin (mTOR)-sterol regulatory element-binding proteins (SREBPs) signaling promotes lipogenesis. However, mTOR inhibitors also displayed a significant side effect of hyperlipidemia. Thus, it is essential to develop mTOR-specific inhibitors to inhibit lipogenesis. Here, we screened the endogenous inhibitors of mTOR, and identified that FKBP38 as a vital regulator of lipid metabolism. FKBP38 decreased the lipid contentandsuppression of the mTOR/P70S6K/SREBPs pathway. 3,5,6,7,8,3',4'-Heptamethoxyflavone (HMF), a citrus flavonoid, was found to target FKBP38 to suppress the mTOR/P70S6K/SREBPs pathway, reduce lipid level, and potently ameliorate hyperlipidemia and insulin resistance in high fat diet (HFD)-fed mice. Our findings suggest that pharmacological intervention by targeting FKBP38 to suppress mTOR/P70S6K/SREBPs pathway is a potential therapeutic strategy for hyperlipidemia, and HMF could be a leading compound for development of anti-hyperlipidemia drugs. [URL='https://www.greenmedinfo.com/article/discovery-potent-fkbp38-agonist-ameliorates-hfd-induced-hyperlipidemia-mtorp70']read more[/URL] [/QUOTE]